|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFB7 |
Gene summary for NDUFB7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFB7 | Gene ID | 4713 |
| Gene name | NADH:ubiquinone oxidoreductase subunit B7 | |
| Gene Alias | B18 | |
| Cytomap | 19p13.12 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P17568 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4713 | NDUFB7 | GSM4909281 | Human | Breast | IDC | 2.13e-07 | 3.63e-01 | 0.21 |
| 4713 | NDUFB7 | GSM4909282 | Human | Breast | IDC | 9.39e-23 | 5.52e-01 | -0.0288 |
| 4713 | NDUFB7 | GSM4909285 | Human | Breast | IDC | 5.46e-25 | 6.05e-01 | 0.21 |
| 4713 | NDUFB7 | GSM4909286 | Human | Breast | IDC | 1.34e-07 | 3.05e-01 | 0.1081 |
| 4713 | NDUFB7 | GSM4909287 | Human | Breast | IDC | 2.99e-27 | 5.38e-01 | 0.2057 |
| 4713 | NDUFB7 | GSM4909288 | Human | Breast | IDC | 3.24e-03 | 1.45e-01 | 0.0988 |
| 4713 | NDUFB7 | GSM4909290 | Human | Breast | IDC | 1.00e-02 | 2.78e-01 | 0.2096 |
| 4713 | NDUFB7 | GSM4909291 | Human | Breast | IDC | 8.81e-13 | 4.31e-01 | 0.1753 |
| 4713 | NDUFB7 | GSM4909293 | Human | Breast | IDC | 1.50e-04 | 2.48e-01 | 0.1581 |
| 4713 | NDUFB7 | GSM4909294 | Human | Breast | IDC | 9.05e-10 | 2.03e-01 | 0.2022 |
| 4713 | NDUFB7 | GSM4909295 | Human | Breast | IDC | 1.35e-03 | 3.27e-01 | 0.0898 |
| 4713 | NDUFB7 | GSM4909296 | Human | Breast | IDC | 4.12e-12 | 5.01e-02 | 0.1524 |
| 4713 | NDUFB7 | GSM4909297 | Human | Breast | IDC | 4.19e-21 | -9.47e-02 | 0.1517 |
| 4713 | NDUFB7 | GSM4909298 | Human | Breast | IDC | 7.57e-16 | 4.82e-01 | 0.1551 |
| 4713 | NDUFB7 | GSM4909301 | Human | Breast | IDC | 3.46e-34 | 5.89e-01 | 0.1577 |
| 4713 | NDUFB7 | GSM4909302 | Human | Breast | IDC | 5.83e-07 | 2.01e-01 | 0.1545 |
| 4713 | NDUFB7 | GSM4909304 | Human | Breast | IDC | 9.19e-17 | 4.67e-01 | 0.1636 |
| 4713 | NDUFB7 | GSM4909306 | Human | Breast | IDC | 1.60e-13 | 4.27e-01 | 0.1564 |
| 4713 | NDUFB7 | GSM4909307 | Human | Breast | IDC | 1.99e-12 | 3.90e-01 | 0.1569 |
| 4713 | NDUFB7 | GSM4909308 | Human | Breast | IDC | 8.68e-06 | 3.08e-01 | 0.158 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004277515 | Endometrium | EEC | mitochondrial ATP synthesis coupled electron transport | 49/2168 | 95/18723 | 1.11e-21 | 9.50e-19 | 49 |
| GO:001964615 | Endometrium | EEC | aerobic electron transport chain | 45/2168 | 87/18723 | 4.34e-20 | 3.26e-17 | 45 |
| GO:001598015 | Endometrium | EEC | energy derivation by oxidation of organic compounds | 97/2168 | 318/18723 | 5.37e-20 | 3.58e-17 | 97 |
| GO:002290415 | Endometrium | EEC | respiratory electron transport chain | 52/2168 | 114/18723 | 7.97e-20 | 4.78e-17 | 52 |
| GO:000609115 | Endometrium | EEC | generation of precursor metabolites and energy | 125/2168 | 490/18723 | 3.76e-18 | 1.88e-15 | 125 |
| GO:002290015 | Endometrium | EEC | electron transport chain | 61/2168 | 175/18723 | 4.60e-16 | 1.84e-13 | 61 |
| GO:000612015 | Endometrium | EEC | mitochondrial electron transport, NADH to ubiquinone | 26/2168 | 51/18723 | 5.31e-12 | 8.85e-10 | 26 |
| GO:001025715 | Endometrium | EEC | NADH dehydrogenase complex assembly | 25/2168 | 57/18723 | 8.26e-10 | 7.51e-08 | 25 |
| GO:003298115 | Endometrium | EEC | mitochondrial respiratory chain complex I assembly | 25/2168 | 57/18723 | 8.26e-10 | 7.51e-08 | 25 |
| GO:003310815 | Endometrium | EEC | mitochondrial respiratory chain complex assembly | 31/2168 | 93/18723 | 2.46e-08 | 1.45e-06 | 31 |
| GO:000611920 | Esophagus | HGIN | oxidative phosphorylation | 69/2587 | 141/18723 | 1.37e-23 | 2.05e-20 | 69 |
| GO:000906020 | Esophagus | HGIN | aerobic respiration | 81/2587 | 189/18723 | 1.07e-22 | 9.26e-20 | 81 |
| GO:004603427 | Esophagus | HGIN | ATP metabolic process | 101/2587 | 277/18723 | 1.53e-21 | 1.02e-18 | 101 |
| GO:000609120 | Esophagus | HGIN | generation of precursor metabolites and energy | 145/2587 | 490/18723 | 3.41e-20 | 2.04e-17 | 145 |
| GO:004533320 | Esophagus | HGIN | cellular respiration | 86/2587 | 230/18723 | 2.41e-19 | 1.20e-16 | 86 |
| GO:001598020 | Esophagus | HGIN | energy derivation by oxidation of organic compounds | 105/2587 | 318/18723 | 1.16e-18 | 4.99e-16 | 105 |
| GO:004277320 | Esophagus | HGIN | ATP synthesis coupled electron transport | 49/2587 | 95/18723 | 2.21e-18 | 7.36e-16 | 49 |
| GO:004277520 | Esophagus | HGIN | mitochondrial ATP synthesis coupled electron transport | 49/2587 | 95/18723 | 2.21e-18 | 7.36e-16 | 49 |
| GO:003310820 | Esophagus | HGIN | mitochondrial respiratory chain complex assembly | 47/2587 | 93/18723 | 3.15e-17 | 8.60e-15 | 47 |
| GO:002290420 | Esophagus | HGIN | respiratory electron transport chain | 51/2587 | 114/18723 | 9.63e-16 | 2.41e-13 | 51 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0472316 | Breast | Precancer | Retrograde endocannabinoid signaling | 25/684 | 148/8465 | 3.05e-04 | 2.47e-03 | 1.89e-03 | 25 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFB7 | SNV | Missense_Mutation | rs748997502 | c.194G>A | p.Arg65Gln | p.R65Q | P17568 | protein_coding | tolerated(0.4) | benign(0.007) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| NDUFB7 | SNV | Missense_Mutation | c.361G>C | p.Glu121Gln | p.E121Q | P17568 | protein_coding | tolerated(0.22) | benign(0) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NDUFB7 | SNV | Missense_Mutation | novel | c.101N>T | p.Arg34Leu | p.R34L | P17568 | protein_coding | deleterious(0.01) | benign(0.11) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NDUFB7 | SNV | Missense_Mutation | c.361G>C | p.Glu121Gln | p.E121Q | P17568 | protein_coding | tolerated(0.22) | benign(0) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| NDUFB7 | SNV | Missense_Mutation | c.308N>G | p.Glu103Gly | p.E103G | P17568 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
| NDUFB7 | SNV | Missense_Mutation | c.236N>T | p.Ala79Val | p.A79V | P17568 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NDUFB7 | SNV | Missense_Mutation | rs779753213 | c.146N>T | p.Ala49Val | p.A49V | P17568 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NDUFB7 | SNV | Missense_Mutation | c.231N>A | p.Phe77Leu | p.F77L | P17568 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NDUFB7 | SNV | Missense_Mutation | novel | c.277C>T | p.Arg93Cys | p.R93C | P17568 | protein_coding | tolerated(0.06) | possibly_damaging(0.657) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NDUFB7 | SNV | Missense_Mutation | c.193N>G | p.Arg65Gly | p.R65G | P17568 | protein_coding | tolerated(0.16) | benign(0.185) | TCGA-BG-A0M2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4713 | NDUFB7 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE | |
| 4713 | NDUFB7 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4713 | NDUFB7 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |